RxDoctor Payments DataLook up a doctor →

Aimee Borazanci, MD

Neurology · Tulsa, OKNPI 1053522847

Payments from drug & device makers

$1,902,940in general payments, 2019–2025

Across 318 payments — averaging $5984.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$925K
  • AbbVie$512K
  • EMD Serono, Inc.$136K
  • F. Hoffmann-la Roche AG$97K
  • Roche Products Limited$61K
  • Biogen$47K
  • plus $125K from 7 others

What the payments were for

  • Consulting fees$27,54337%
  • Speaking & faculty fees$41,74256%
  • Travel & lodging$3,8265%
  • Food & beverage$1,8883%

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,902,940 in reported general payments places this provider in the 95th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$230,705
Medicare patients
167
Services billed
4,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab59$608,292
AubagioTeriflunomide46$427,518
CopaxoneGlatiramer Acetate68$416,130
AmpyraDalfampridine46$194,808
TecfideraDimethyl Fumarate13$122,269
BetaseronInterferon Beta-1b12$120,446
NuedextaDextromethorphan Hbr/Quinidine52$88,148
Dalfampridine ErDalfampridine164$44,363
Glatiramer Acetate18$28,298
Teriflunomide30$21,922
Dimethyl Fumarate35$20,793
FingolimodFingolimod Hcl31$6,615
Baclofen265$6,071
Modafinil104$5,683
Carbamazepine ErCarbamazepine29$3,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$41,535$427,51846 claims
BiogenTecfidera$47,047$122,26913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 152 neurology providers in Oklahoma.

Other neurology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →